PTN — Palatin Technologies Share News
0.000.00%
Last trade - 00:00- $9.10m
- $1.61m
- $13.19m
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity
Brief: NYSE American To Commence Delisting Proceedings Against Palatin Technologies
Brief: Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering
Brief: Palatin Expects $11.5 Million Financing To Cure NYSE American Delisting Notice
Brief: Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Brief: Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study Of Mc4r Agonist Bremelanotide And Tirzepatide
Brief: Palatin Appeals NYSE American Notice Of Delisting
Brief: Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal
Brief: Palatin Technologies Files Offering Up To 17.3 Million Shares Of Common Stock Together With Series F Common Stock Purchase Warrants
Brief: Palatin Announces Positive Topline Results From Phase 2 Ulcerative Colitis (UC) Study Of Oral Melanocortin-1 Receptor Agonist Pl8177
Brief: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies down after launching stock sale
Brief: Palatin Technologies Says Co To Sell Up To $6 Million In Common Stock
Brief: Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Brief: Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide
Brief: Palatin Announces Phase IIb Breakout Study Results In Patients With Type 2 Diabetic Nephropathy